SCHEMBL29947773

SCHEMBL29947773

Cc1ccccc1C(=O)Nc1ccc(S(=O)(=O)N[C@@H]2CCN(C(=O)[C@H](C)N)C[C@H]2C)c2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CCR8 P51685 20/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1339797 1.00 CCR8 (0.64) CCR8
SCHEMBL1339606 1.00 CCR8 (0.64) CCR8
SCHEMBL1338570 1.00 CCR8 (0.64) CCR8
SCHEMBL1340828 1.00 CCR8 (0.64) CCR8
SCHEMBL1337576 1.00 CCR8 (0.64) CCR8
SCHEMBL1339605 1.00 CCR8 (0.64) CCR8
SCHEMBL1337578 1.00 CCR8 (0.64) CCR8
SCHEMBL1337574 1.00 CCR8 (0.64) CCR8
SCHEMBL1338940 0.96 CCR8 (0.58) CCR8
SCHEMBL1337635 0.96 CCR8 (0.58) CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121406567-B Composition and culture solution for promoting bovine gene editing cloned embryo development and application thereof 中国农业大学 2026-03-27 CN disclosed
EP-4705346-A2 ANTI-CCR8 ANTIBODIES, CONJUGATES, AND USES THEREOF Abilita Bio, Inc. (US) 2026-03-11 EP disclosed
CN-121406567-A Composition and culture solution for promoting bovine gene editing cloned embryo development and application thereof 中国农业大学 2026-01-27 CN disclosed
US-20250092146-A1 ANTI-CCR8 ANTIBODIES, CONJUGATES, AND USES THEREOF ABILITA BIO, INC. D/B/A ABILITA THERAPEUTICS, INC. 2025-03-20 US disclosed
WO-2024227083-A2 ANTI-CCR8 ANTIBODIES, CONJUGATES, AND USES THEREOF Abilita Bio, Inc. (US) 2024-10-31 WO disclosed
WO-2024133292-A1 NOVEL CCR8 ANTAGONISTS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-27 WO disclosed
US-20240175873-A1 METHODS FOR THE DIAGNOSIS AND TREATMENT OF T CELL-LYMPHOMAS ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP) (FR) 2024-05-30 US disclosed
EP-4313317-A1 METHODS FOR THE DIAGNOSIS AND TREATMENT OF T CELL-LYMPHOMAS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2024-02-07 EP disclosed
WO-2024003310-A1 METHODS FOR THE DIAGNOSIS AND TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA Institut National de la Santé et de la Recherche Médicale (FR) 2024-01-04 WO disclosed
CN-117177771-A Method for diagnosing and treating T cell lymphoma INSERM(法国国家健康医学研究院) 2023-12-05 CN disclosed
WO-2022200303-A1 METHODS FOR THE DIAGNOSIS AND TREATMENT OF T CELL-LYMPHOMAS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2022-09-29 WO disclosed